Continuous subcutaneous use of levetiracetam: A retrospective review of tolerability and clinical effects

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 28, Issue 4, 2014, Pages 371-377

  Rémi, Constanze ^a   Lorenzl, Stefan ^b   Vyhnalek, Birgit ^c   Rastorfer, Karin ^d   Feddersen, Berend ^e  

^a UNIVERSITY OF MUNICH   (Germany)

^b Departments of Palliative Medicine and Neurology   (Germany)

^c Department of Palliative Medicine ^*  (Germany)

^d Outpatient Service Team for Infusion and Nutrition Therapy   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Epilepsy; Levetiracetam; Status epilepticus; Subcutaneous

Indexed keywords

CLONIDINE; DEXAMETHASONE; DIPYRONE; ETIRACETAM; GLYCOPYRRONIUM BROMIDE; HALOPERIDOL; HYDROMORPHONE; LEVOMEPROMAZINE; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; PHENYTOIN; SCOPOLAMINE BUTYL BROMIDE; ANTICONVULSIVE AGENT; PIRACETAM;

AGED; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EPILEPTIC STATE; FEMALE; HOSPITAL PATIENT; HUMAN; INJECTION SITE IRRITATION; INJECTION SITE PAIN; MALE; MEDICAL RECORD REVIEW; OSMOLARITY; OUTPATIENT; PALLIATIVE THERAPY; SEIZURE; SKIN REDNESS; TREATMENT DURATION; ADULT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG COMBINATION; EPILEPSY; MIDDLE AGED; PAIN; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PAIN; PIRACETAM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84911903186     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2014.959234     Document Type: Article

References (28)

1. Morris HH, Estes LM, Gilmore R, et al. Chronic intractable epilepsy as the only symptom of primary brain tumor. Epilepsia. 1993 Nov-Dec;34(6):1038-1043. PubMed PMID: 8243354. Epub 1993/11/01.eng.
2. Hauser AW, Annegers FJ, Kurland TL. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993 May-Jun;34(3):453-468. PubMed PMID: 8504780. Epub 1993/05/01.eng.
3. Rona S, Rosenow F, Arnold S, et al. A semiological classifcation of status epilepticus. Epileptic Disord. 2005 Mar;7(1):5-12. PubMed PMID: 15741134. Epub 2005/03/03.eng.
4. Lorenzl S, Mayer S, Noachtar S, et al. Nonconvulsive status epilepticus in terminally ill patients-a diagnostic and therapeutic challenge. J Pain Symptom Manage. 2008 Aug;36(2):200-205. PubMed PMID: 18395399. Epub 2008/04/09.eng.
5. Corporation G. YouScript® Seattle, WA2013 [cited 2013 13.2.2013]. Available from: http://www.youscript.net/.
6. Surges R, Volynski EK, Walker CM. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord. 2008 Jul;1(1):13-24. PubMed PMID: 21180561. Pubmed Central PMCID: 3002539. Epub 2008/07/01.eng.
7. Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011 Oct;52 Suppl 8:35-38. PubMed PMID: 21967358. Epub 2011/10/14.eng.
8. Feddersen B, Trinka, E. [Status epilepticus]. Nervenarzt. 2012 Feb;83(2):187-194. PubMed PMID: 22249602. Epub 2012/01/18. Status epilepticus. ger.
9. Glien M, Brandt C, Potschka H, et al. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia. 2002 Apr;43(4):350-7. PubMed PMID: 11952764. Epub 2002/04/16.eng.
10. Lopez-Saca MJ, Vaquero J, Larumbe A, et al. Repeated Use of Subcutaneous Levetiracetam in a Palliative Care Patient. J Pain Symptom Manage. 2013 Mar 24. PubMed PMID: 23535323. Epub 2013/03/29.Eng.
11. Fonzo-Christe, Caroline, Vukasovic, Caroline, Wasilewski-Rasca, Anne-Florence, et al. Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review. Palliative Medicine. 2005;19:208-219.
12. Menahem S, Shvartzman, P. Continuous subcutaneous delivery of medications for home care palliative patients-using an infusion set or a pump? Support Care Cancer. 2010 Sep;18(9):1165-1170. PubMed PMID: 19787380. Epub 2009/09/30.eng.
13. Mtten, Trevor. Subcutaneous drug infusions: a review of problems and solutions. International Journal of Palliative Nursing. 2001;7(2):75-85.
14. Herndon MC, Fike SD. Continuous Subcutaneous Infusion Practices of United States Hospices. J Pain Symptom Manage. 2001 12/2001;22(6):1027-1034.
15. Fisher SR, Boas vE W, Blume W, et al. Epileptic seizures and epilepsy: defnitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005 Apr;46(4):470-472. PubMed PMID: 15816939. Epub 2005/04/09.eng.
16. Mundipharma. Personal Communication. 2013.
17. UCB. Personal Communication. 2010.
18. Ege I, Feldmann F, Lambert K, Moller A, Nett C, Pecar A, et al. PAD i.v. 3 ed. München: Zuckschwerdt Verlag; 2009.
19. Mbizvo KG, Dixon P, Hutton LJ, et al. Levetiracetam addon for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev. 2012;9:CD001901. PubMed PMID: 22972056. Epub 2012/09/14.eng.
20. Msra KU, Kalita J, Maurya KP. Levetiracetam versus lo-razepam in status epilepticus: a randomized, open labeled pilot study. Journal of neurology. 2012 Apr;259(4):645-648. PubMed PMID: 21898137. Epub 2011/09/08.eng.
21. Graham, F. Syringe drivers and subcutaneous sites: a review. European Journal of Palliative Care. 2006;13(4):138-141.
22. Dunne K, Sullivan K, Garvey A, et al. An audit of subcutaneous syringe drivers in a non-specialist hospital. Int J Palliat Nurs. 2000 May;6(5):214-219. PubMed PMID: 12419992.
23. Wilcock A, Jacob KJ, Charlesworth S, et al. Drugs given by a syringe driver: a prospective multicentre survey of palliative care services in the UK. Palliat Med. 2006 Oct;20(7):661-664. PubMed PMID: 17060264. Epub 2006/10/25.eng.
24. Schneider JJ, Wilson MK, Ravenscroft JP. A study of the osmolality and pH of subcutaneous drug infusion solutions. Australian Journal of Hospital Pharmacy. 1997;27:29-31.
25. Infusionzubereitungen Europaisches Arzneibuch (European Pharmacopoeia Ph Eur) 70 Ausgabe Grundwerk 2011 Band 1. 72011. p. 1100.
26. Parenteralia 5.2/0520. Arzneibuchkommentar (European Pharmacopoeia Ph Eur; commentary) Gesamtwerk einschliesslich 43 Aktualisierungslieferung 2012. Stuttgart, Eschborn: Wis-senschaftliche Verlagsgesellschaft Stuttgart Govi-Verlag GmbH; 2012.
27. Jauch WK, Schregel W, Stanga Z, et al. 9 Technik und Probleme der Zugange in der parenteralen Ernahrung. Aktuel Ernahrungsmed. 2007 04.03.2008;32(S 1):S41-S53. PubMed PMID: 101055S2006951876. De.
28. UCB. Prescribing Information (German) Keppra® 100 mg/ml Konzentrat zur Herstellung einer Infusionslosung: Rote Liste Service GmbH; 2014 [updated 01.2014; cited 2014 10.08.2014]. Available from: http://www.fachinfo.de